"I and the board are very pleased to welcome Anders as the new CEO of PHI. His solid background and experience in the life science industry is a strong asset to us. I would also like to extend a warm thank you to Patrik for his time as CEO. Under Patrik's leadership, the company has expanded its market share and deepened collaborations with academic and industry partners, establishing a great foundation for future success. With Anders' sharp expertise in management within this innovation-driven, high-tech sector, combined with his experience across various geographies and business areas, Anders is the right person to continue leading PHI. Together with the management team and the board, he will drive our future development as we focus on expanding from pre-clinical research into the clinical market and the emerging regenerative medicine field," says Goran Dubravčić, Chairman of the Board.

Starting November 1, 2024, Anders Månsson will succeed Patrik Eschricht as CEO of PHI. Månsson brings over 25 years of experience in the international Health & Life Sciences field, having held senior-level positions in both large multinationals and smaller biotech companies. Most recently, he served as CEO of Oncoinvent ASA, and he has also held numerous leadership roles, including CEO, Chairman, and Board Member positions. He is currently a board member of EQL Pharma AB and a Partner and Board Member at Immetric AB. Månsson's previous roles also include CEO of LIDDS AB, the biopharmaceutical company RhoVac AB, and stem cell research-based company Amniotics AB. He studied for an Executive MBA at Business School Lausanne, Switzerland.

As CEO of PHI, Anders will be responsible for driving the company's future development, with a particular focus on R&D, product development, and establishing PHI as a leader in non-invasive cell quality control technologies. Current CEO Patrik Eschricht will continue in his current role until November 1, 2024, and will ensure a smooth handover to Anders.

"PHI is on an incredibly exciting journey as it continues to solidify its position as a leader in non-invasive cell quality control technologies. I am honored to take on the role of CEO, and I look forward to working with the team to accelerate product development, expand our global reach, and strengthen our presence in key markets. Together, we will build on the strong foundation that has been laid, and I am excited to contribute to the next phase of PHI's growth," comments Anders Månsson.